RNA-Seq of paired diagnosis and relapse AML specimens with healthy controls

Despite therapeutic advances, acute myeloid leukemia (AML) patients remains a clinically challenging malignancy, highlighting the continued need for identification of previously unrecognized targetable drivers of the disease to further improve current treatment options. Aberrantly expressed genes are associated with AML pathogenesis and can function as disease drivers. Targeting of their function or related pathways has shown promising results in identifying novel therapeutic targets. We performed RNA sequencing (RNA-Seq) of AML patients specimens to identify aberrantly expressed AML genes associated with AML progression. The dataset comprised of two cohorts (I: n = 29 and II: n = 30), each cohort containing matched diagnosis-relapse pairs along with corresponding healthy control specimens (cohort I: n = 3 and cohort II: n = 5) derived from CD34+ normal bone marrow cells. All the diagnosis patients received combination intensive chemotherapy (7+3: continuous infusion of cytarabine for 7 days combined with anthracycline on days 1-3) during their induction treatment and all patients achieved remission after induction treatment. This sumission provides raw gene-level read counts to facilitate differential gene expression analyses between diagnosis and relapse specimens and relative to healthy controls. The fastq files for the data can be accessed through dbGap accession number phs001027.